Loading...

The Belfer Center is part of Dana-Farber Cancer Institute. We advance discoveries and therapies to translate today’s science into tomorrow’s treatments.
We accelerate discovery and development of the next generation of targeted and immune-based therapies
We integrate academic and industrial research to drive clinical trials and improve patients’ lives

Loading...

Spotlight

Twitter feed

Unable to load Tweets

Follow

Recent publications

Targeting TBK1 to overcome resistance to cancer immunotherapy.
Nature. 2023 Mar.

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.
N Engl J Med. 2023 Jan 5.

All publications

Announcements

We are proud of our alumni and we celebrate their successes! Read what Allison O’Connell and Kristin DePeaux say about their time at the Belfer.

Research

Target identification and validation

Drug discovery and development

Clinical science and correlatives

Strategic alliances

Graphic showing circular relationship of research, medicine, and industry

Our strategic alliances drive research innovations and lead to improved therapies to benefit cancer patients

Collaborate with us

Our people

Our team

Our culture

Donor highlight

Robert and Renée Belfer’s transformative cumulative Dana-Farber investment of more than $25 million launched the Robert A. and Renée E. Belfer Center for Applied Cancer Science. Their generosity enabled the Belfer Center to integrate its scientific teams, produce innovative cancer models, partner with industry leaders, and accelerate the development of revolutionary therapies to treat cancer. We are grateful for their vision and incredible support.

The Belfer Center is part of Dana-Farber Cancer Institute. We advance discoveries and therapies to translate today’s science into tomorrow’s treatments.

We accelerate discovery and development of the next generation of targeted and immune-based therapies

We integrate academic and industrial research to drive clinical trials and improve patients’ lives